• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Bio-Techne Corp

    5/30/25 4:30:27 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECH alert in real time by email
    SD 1 tech-20250530xsd.htm SD

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    FORM SD


    SPECIALIZED DISCLOSURE REPORT


    BIO-TECHNE CORPORATION

    (Exact name of registrant as specified in its charter)


    ​

    Minnesota

    000-17272

    41-1427402

    (State or other jurisdiction of
    incorporation or organization)

    (Commission
    File Number)

    (I.R.S. Employer
    Identification No.)

    ​

    614 McKinley Place NE Minneapolis, MN

    55413

    (Address of principal executive offices)

    (Zip Code)

    ​

    Shane V. Bohnen (612) 851-4841

    (Name and telephone number, including area code, of the person to contact in connection with this report)


    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

    ​

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

    ​

    ​

    ​

    1


    ​

    SECTION 1 – CONFLICT MINERALS DISCLOSURE

    Item 1.01 Conflict Minerals Disclosure and Report

    Most of the products Bio-Techne manufactures or contracts to manufacture do not contain conflict minerals. However, under our ProteinSimple brand included in our Analytical Solutions Division, we sell instruments, some of which include tin, tungsten, tantalum and/or gold (“3TG”). We also sell two other small groups of reagent products, one under our Novus Biologicals and R&D Systems brands that contains 3TG. These product lines collectively are the subject of this Report.

    ​

    Conflict Minerals Disclosure

    A copy of Bio-Techne Corporation’s Conflict Minerals Report is provided as Exhibit 1.01 hereto and is publicly available at www.bio-techne.com .

    Item 1.02 Exhibit

    As specified in Section 2, Item 2.01 of this Form SD, the Company is hereby filing its Conflict Minerals Report as Exhibit 1.01 to this Form SD.

    SECTION 2 – EXHIBITS

    Item 2.01 Exhibits

    Exhibit 1.01 – Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

    ​

    2


    ​

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Date: May 30, 2025

    By:

    /s/ Shane V. Bohnen

    ​

    Name:

    Shane V. Bohnen

    ​

    Title:

    Senior Vice President, General Counsel and Secretary

    ​

    3


    Get the next $TECH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TECH

    DatePrice TargetRatingAnalyst
    5/30/2025$59.00Overweight
    Wells Fargo
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/18/2025$75.00Outperform
    Evercore ISI
    2/19/2025$88.00 → $68.00Outperform → Neutral
    Robert W. Baird
    5/22/2024$85.00Buy → Neutral
    Citigroup
    2/8/2024$80.00Sector Outperform
    Scotiabank
    2/2/2024$65.00Buy → Hold
    Stifel
    12/7/2023$80.00Buy
    UBS
    More analyst ratings

    $TECH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Herr Amy E. exercised 1,280 shares at a strike of $44.33 and sold $63,705 worth of shares (1,280 units at $49.77) (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      6/11/25 4:20:06 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Higgins John L exercised 12,000 shares at a strike of $21.84, increasing direct ownership by 25% to 60,196 units (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      5/5/25 4:18:21 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP - General Counsel Bohnen Shane converted options into 2,260 shares and covered exercise/tax liability with 747 shares, increasing direct ownership by 90% to 3,194 units (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      4/7/25 4:25:38 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

      ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India. "The blood cancer burden on India's population is substantial, around 120,000 new cases of lymphoma, leukemia, and multiple myeloma are diagnosed each year. Unfortunately, almost 70,000 Indians will die every year from these afflictions, devastating the lives of their families and communities. To afford access to all Indian patients in need,

      6/10/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Techne to Present at Investor Conferences

      MINNEAPOLIS, May 29, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that it will present at the following investor conferences: William Blair 45th Annual Growth Stock ConferenceJune 3, 20252:40 PM CDT Jefferies Global Healthcare ConferenceJune 4, 20253:45 PM EDT Goldman Sachs 46th Annual Global Healthcare ConferenceJune 10, 202510:40 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-TechneBio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and cli

      5/29/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA)

      ST. PAUL, Minn., May 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ:TECH) and CellReady announced today three G-Rex Grants that have been awarded to faculty members at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA). The funding totaling $1,025,000 will support the translation of various cell and gene therapy initiatives into the clinic. Dr. Mohamed Abou-el-Enein, Executive Director of the USC/CHLA Cell Therapy Program and Founding Director of the cGMP Facility, received a $300,000 G-Rex Grant to further support the development of a novel non-viral manufacturing platform for CA

      5/14/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on Bio-Techne with a new price target

      Wells Fargo initiated coverage of Bio-Techne with a rating of Overweight and set a new price target of $59.00

      5/30/25 8:40:12 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Techne downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Bio-Techne from Overweight to Sector Weight

      4/9/25 8:34:38 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Bio-Techne with a new price target

      Evercore ISI initiated coverage of Bio-Techne with a rating of Outperform and set a new price target of $75.00

      3/18/25 7:57:08 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    SEC Filings

    See more
    • SEC Form 144 filed by Bio-Techne Corp

      144 - BIO-TECHNE Corp (0000842023) (Subject)

      6/9/25 4:19:36 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SD filed by Bio-Techne Corp

      SD - BIO-TECHNE Corp (0000842023) (Filer)

      5/30/25 4:30:27 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Bio-Techne Corp

      SCHEDULE 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

      5/14/25 10:45:26 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bio-Techne Corp

      SC 13G - BIO-TECHNE Corp (0000842023) (Subject)

      11/14/24 1:22:36 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

      SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

      2/13/24 5:00:46 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

      SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

      2/9/23 11:12:40 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care